{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:09:38Z","timestamp":1773274178978,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ejphar.2012.11.010","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T17:18:10Z","timestamp":1353518290000},"page":"292-298","source":"Crossref","is-referenced-by-count":26,"title":["Effects of amylin and bupropion\/naltrexone on food intake and body weight are interactive in rodent models"],"prefix":"10.1016","volume":"698","author":[{"given":"Jason R.","family":"Clapper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Athanacio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Wittmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pete S.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Parkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2012.11.010_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/oby.2002.86","article-title":"Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial","volume":"10","author":"Anderson","year":"2002","journal-title":"Obes. Res."},{"key":"10.1016\/j.ejphar.2012.11.010_bib2","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/oby.2009.478","article-title":"Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial","volume":"18","author":"Aronne","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ejphar.2012.11.010_bib3","first-page":"395","article-title":"Bupropion: a review of its mechanism of antidepressant activity","volume":"56","author":"Ascher","year":"1995","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2012.11.010_bib4","first-page":"178","article-title":"Opioid regulation of food intake and body weight in humans","volume":"46","author":"Atkinson","year":"1987","journal-title":"Fed Process."},{"key":"10.1016\/j.ejphar.2012.11.010_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/clpt.1985.197","article-title":"Effects of long-term therapy with naltrexone on body weight in obesity","volume":"38","author":"Atkinson","year":"1985","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2012.11.010_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0031-9384(98)00110-3","article-title":"Synergy between amylin and cholecystokinin for inhibition of food intake in mice","volume":"64","author":"Bhavsar","year":"1998","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejphar.2012.11.010_bib7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.npp.1301155","article-title":"Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice","volume":"32","author":"Billes","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2012.11.010_bib8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/sj.npp.1301526","article-title":"Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis","volume":"33","author":"Billes","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2012.11.010_bib9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nn1455","article-title":"Anatomy and regulation of the central melanocortin system","volume":"8","author":"Cone","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2012.11.010_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejphar.2010.10.029","article-title":"Differential effects of chronic naltrexone treatment on food intake patterns and body weight in rats depend on their food deprivation status","volume":"650","author":"De Tomasi","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.11.010_bib11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1586\/14737175.6.9.1249","article-title":"Bupropion: pharmacology and therapeutic applications","volume":"6","author":"Foley","year":"2006","journal-title":"Expert Rev. Neurother"},{"key":"10.1016\/j.ejphar.2012.11.010_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/14737175.7.1.17","article-title":"Bupropion for weight reduction","volume":"7","author":"Gadde","year":"2007","journal-title":"Expert Rev. Neurother"},{"key":"10.1016\/j.ejphar.2012.11.010_bib13","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1210\/jc.2009-1350","article-title":"Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo","volume":"94","author":"Greenway","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2012.11.010_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.ejphar.2012.11.010_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ejphar.2012.11.010_bib16","article-title":"A review of late-stage CNS drug candidates for the treatment of obesity","author":"Heal","year":"2012","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.ejphar.2012.11.010_bib17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","article-title":"Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients","volume":"12","author":"Hollander","year":"2004","journal-title":"Obes. Res."},{"key":"10.1016\/j.ejphar.2012.11.010_bib18","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00018-011-0905-1","article-title":"Control of energy homeostasis by amylin","volume":"69","author":"Lutz","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2012.11.010_bib19","first-page":"347","article-title":"A controlled trial of naltrexone in obese humans","volume":"9","author":"Malcolm","year":"1985","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejphar.2012.11.010_bib20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2337\/diab.47.2.294","article-title":"Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting and [corrected] in ob\/ob and db\/db mice, but is stimulated by leptin","volume":"47","author":"Mizuno","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2012.11.010_bib21","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced weight loss with pramlintide\/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ejphar.2012.11.010_bib22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.mehy.2010.09.002","article-title":"Hypothalamic opioid-melanocortin appetitive balance and addictive craving","volume":"76","author":"Reece","year":"2011","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejphar.2012.11.010_bib23","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1210\/en.2007-0898","article-title":"Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity","volume":"148","author":"Roth","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2012.11.010_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/j.1463-1326.2012.01570.x","article-title":"Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents","author":"Roth","year":"2012","journal-title":"Diabetes Obes. Metab"},{"key":"10.1016\/j.ejphar.2012.11.010_bib25","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1210\/en.2006-0393","article-title":"Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression","volume":"147","author":"Roth","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2012.11.010_bib26","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.0706473105","article-title":"Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies","volume":"105","author":"Roth","year":"2008","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2012.11.010_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainres.2010.01.027","article-title":"\u201cWeighing in\u201d on synergy: preclinical research on neurohormonal anti-obesity combinations","volume":"1350","author":"Roth","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2012.11.010_bib28","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/ijo.2008.91","article-title":"Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats","volume":"32","author":"Roth","year":"2008","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.ejphar.2012.11.010_bib29","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1210\/en.2008-0770","article-title":"Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms","volume":"149","author":"Trevaskis","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2012.11.010_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.physbeh.2010.02.023","article-title":"Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin?","volume":"100","author":"Trevaskis","year":"2010","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejphar.2012.11.010_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1210\/en.2009-0546","article-title":"Mechanisms of amylin\/leptin synergy in rodent models","volume":"151","author":"Turek","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2012.11.010_bib32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ejphar.2012.11.010_bib33","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1210\/endo.140.5.6728","article-title":"Physiological and anatomical circuitry between Agouti-related protein and leptin signaling","volume":"140","author":"Wilson","year":"1999","journal-title":"Endocrinology"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912009417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912009417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T17:35:26Z","timestamp":1562348126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299912009417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":33,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0014299912009417"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2012.11.010","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}